Prognostic value of the dynamics of M-type phospholipase A2 receptor antibody titers in patients with idiopathic membranous nephropathy treated with two different immunosuppression regimens

Abstract Context: The dynamics of anti-phospholipase A2 antibody titers during treatment could predict clinical responses in patients with membranous nephropathy. Objectives: We analyzed the predictive value of the dynamics of these antibodies on clinical responses. Materials and methods: The serum antibody levels were measured before and during treatment in 79 patients with anti-phospholipase A2 receptor antibody membranous nephropathy treated with two different immunosuppression regimens Results: In both groups of patients, the relative reduction in antibody titers at 3 and 6 months preceded and predicted the clinical responses. Conclusions: Antibody titer dynamics was useful for predicting clinical responses.

[1]  M. Goicoechea,et al.  Predictors of response and relapse in patients with idiopathic membranous nephropathy treated with tacrolimus. , 2015, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[2]  J. Wetzels,et al.  Association of anti-PLA₂R antibodies with outcomes after immunosuppressive therapy in idiopathic membranous nephropathy. , 2014, Clinical journal of the American Society of Nephrology : CJASN.

[3]  U. Panzer,et al.  Phospholipase A2 receptor autoantibodies and clinical outcome in patients with primary membranous nephropathy. , 2014, Journal of the American Society of Nephrology : JASN.

[4]  M. Fritzler,et al.  Antiphospholipase A2 Receptor Autoantibodies: A Comparison of Three Different Immunoassays for the Diagnosis of Idiopathic Membranous Nephropathy , 2014, Journal of immunology research.

[5]  N. Valtierra,et al.  Evolution of antibody titre against the M-type phospholipase A2 receptor and clinical response in idiopathic membranous nephropathy patients treated with tacrolimus. , 2014, Nefrologia : publicacion oficial de la Sociedad Espanola Nefrologia.

[6]  A. Segarra-Medrano,et al.  Evolución del título de anticuerpos contra el receptor tipo M de la fosfolipasa A2 y respuesta clínica en pacientes con nefropatía membranosa idiopática tratados con tacrolimus , 2014 .

[7]  J. Wetzels,et al.  Long-term outcomes in idiopathic membranous nephropathy using a restrictive treatment strategy. , 2014, Journal of the American Society of Nephrology : JASN.

[8]  H. Trachtman,et al.  KDOQI US commentary on the 2012 KDIGO clinical practice guideline for glomerulonephritis. , 2013, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[9]  J. Wetzels,et al.  Treatment of idiopathic membranous nephropathy , 2013, Nature Reviews Nephrology.

[10]  L. McWilliam,et al.  Anti-PLA2R antibodies measured by ELISA predict long-term outcome in a prevalent population of patients with idiopathic membranous nephropathy. , 2013, Kidney international.

[11]  J. Wetzels,et al.  anti-Pla 2 r antibodies in membranous nephropathy: ready for routine clinical practice? , 2012 .

[12]  U. Panzer,et al.  An immunofluorescence test for phospholipase-A₂-receptor antibodies and its clinical usefulness in patients with membranous glomerulonephritis. , 2011, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[13]  David M. Beck,et al.  Rituximab-induced depletion of anti-PLA2R autoantibodies predicts response in membranous nephropathy. , 2011, Journal of the American Society of Nephrology : JASN.

[14]  David M. Beck,et al.  Anti-phospholipase A₂ receptor antibodies correlate with clinical status in idiopathic membranous nephropathy. , 2011, Clinical journal of the American Society of Nephrology : CJASN.

[15]  D. Salant,et al.  Anti-phospholipase A2 receptor antibody in membranous nephropathy. , 2011, Journal of the American Society of Nephrology : JASN.

[16]  David M. Beck,et al.  Anti-Phospholipase A2 Receptor Antibodies Correlate with Clinical Status in Idiopathic Membranous Nephropathy , 2011 .

[17]  克治 桑門.  海外論文紹介 : M-Type Phospholipase A2 Receptor as Target Antigen in Idiopathic Membranous Nephropathy , 2010 .

[18]  C. Schmid,et al.  A new equation to estimate glomerular filtration rate. , 2009, Annals of internal medicine.

[19]  M. Oppermann,et al.  Early versus late start of immunosuppressive therapy in idiopathic membranous nephropathy : a randomized controlled trial , 2009 .

[20]  K. Sud,et al.  A randomized, controlled trial of steroids and cyclophosphamide in adults with nephrotic syndrome caused by idiopathic membranous nephropathy. , 2007, Journal of the American Society of Nephrology : JASN.

[21]  J. Luño,et al.  Tacrolimus monotherapy in membranous nephropathy: a randomized controlled trial. , 2007, Kidney international.

[22]  D. Kerjaschki.  Pathomechanisms and molecular basis of membranous glomerulopathy , 2004, The Lancet.

[23]  L. Hebert,et al.  Cyclosporine in patients with steroid-resistant membranous nephropathy: a randomized trial. , 2001, Kidney international.

[24]  A. Lupo,et al.  A randomized study comparing methylprednisolone plus chlorambucil versus methylprednisolone plus cyclophosphamide in idiopathic membranous nephropathy. , 1998, Journal of the American Society of Nephrology : JASN.

[25]  D. Churchill,et al.  A controlled trial of cyclosporine in patients with progressive membranous nephropathy. Canadian Glomerulonephritis Study Group. , 1995, Kidney international.

[26]  J. Velosa,et al.  Idiopathic membranous nephropathy: the natural history of untreated patients. , 1988, Kidney international.

[27]  A. Pierides,et al.  Idiopathic membranous nephropathy. , 1977, The Quarterly journal of medicine.

[28]  C. F. Anderson,et al.  Controlled trial of cyclophosphamide in idiopathic membranous nephropathy. , 1974, Kidney international.